Scholarlink

<p>Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in animal models and clinical trials have revealed decreased insulin dependence, increased β cell mass, and improved islet graft acceptance. Despite their potential, challenges in quality control, small-scale investigations, functional heterogeneity, and standardization limit the application of these therapies. This review synthesizes the current knowledge and recent outcomes of ADMSC therapies in treating T1D and highlights areas that need further investigation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adipose-derived mesenchymal stromal/stem cells in type 1 diabetes treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月23日

查看全文
  • Vanshika Sood,
  • Hannah Ricioli,
  • George Chigozie Njoku,
  • Rosita Primavera,
  • Susana Dietrich,
  • Avnesh S. Thakor,
  • Flemming Pociot,
  • Reza Yarani

摘要

Adipose tissue-derived mesenchymal stromal/stem cells (ADMSCs) represent a novel therapeutic intervention for Type 1 Diabetes (T1D). The attractiveness of ADMSCs is characterized by their immunomodulatory activities, regenerative properties, and relative ease of access. ADMSC therapies in animal models and clinical trials have revealed decreased insulin dependence, increased β cell mass, and improved islet graft acceptance. Despite their potential, challenges in quality control, small-scale investigations, functional heterogeneity, and standardization limit the application of these therapies. This review synthesizes the current knowledge and recent outcomes of ADMSC therapies in treating T1D and highlights areas that need further investigation.